The Journey of a Sample

Background

As clinical trials evolve towards decentralization and technology integration, the need for effective data governance and sustainability becomes paramount. The scientific community faces pressure to minimize environmental impacts while maintaining quality and efficiency in trial execution. Understanding the journey of biological samples is crucial for enhancing trial resilience and data integrity.

Data Highlights

No numerical data provided in the source material.

Key Findings

• Outdated paper-based processes in sample collection can lead to high query rates and increased material waste.
• Electronic requisition systems can significantly reduce query rates and improve traceability.
• Intelligent inventory management can align supply with actual demand, minimizing surplus and waste.
• Optimized packaging and shipment planning can reduce the environmental impact of sample logistics.
• Efficient cryogenic shipping practices can lead to reductions in carbon emissions.

Clinical Implications

Implementing electronic systems and optimized workflows can enhance the efficiency of sample management in clinical trials. Laboratories should consider sustainability in their study designs to improve both environmental impact and patient experience.

Conclusion

The journey of a biological sample from collection to analysis is critical in ensuring trial integrity and sustainability. Embracing technology and innovative practices can lead to significant improvements in both efficiency and environmental responsibility.

Related Resources & Content

1. the analytical scientist, State-of-the-Art Sample Preparation Roundtable: Part One, 2026 -- State-of-the-Art Sample Preparation Roundtable: Part One
2. the analytical scientist, Accelerating Sample Prep: The Case for Automation, 2026 -- Accelerating Sample Prep: The Case for Automation
3. the analytical scientist, State-of-the-Art Sample Preparation Roundtable: Part Three, 2026 -- State-of-the-Art Sample Preparation Roundtable: Part Three
4. the analytical scientist, State-of-the-Art Sample Preparation Roundtable: Part Two, 2026 -- State-of-the-Art Sample Preparation Roundtable: Part Two
5. ICH E6(R3) Final Guideline, 2025 -- ICH E6(R3) Final Guideline
6. Agreement of treatment effects in decentralised trials versus traditional trials: meta-epidemiological study, The BMJ, 2025 -- Agreement of treatment effects in decentralised trials versus traditional trials
7. Companion diagnostics ('in vitro diagnostics'), European Medicines Agency (EMA) -- Companion diagnostics ('in vitro diagnostics')
8. Scope, Applicability, and Implementation - NCI -- Scope, Applicability, and Implementation
9. https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf
10. Agreement of treatment effects in decentralised trials versus traditional trials: meta-epidemiological study | The BMJ
11. Companion diagnostics ('in vitro diagnostics') | European Medicines Agency (EMA)
12. Scope, Applicability, and Implementation - NCI